Bladder Cancer VL

Pembrolizumab in High-Risk, BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Arjun Balar

Details
In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...

A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse

Details
Ashish Kamat welcomes Karen Sachse, a patient advocate for the Bladder Cancer Advocacy Network (BCAN) who shares her perspective on non muscle-invasive bladder cancer, the various trials that are ongoing, and the future of various studies. As a bladder cancer survivor diagnosed in 2010 at age 54 with high grade non-muscle invasive bladder cancer, she is disease-free since 2014. Biographies: Karen...

How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black

Details
Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...

High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi

Details
Bacillus Calmette-Guerin (BCG) has been the standard of care for patients with non-muscle invasive bladder cancer for decades. However, within five years of the first instillation of BCG therapy, about 50% of tumors recur, and 20% of tumors will progress. To overcome BCG resistance, we need to understand the mechanisms of a BCG therapeutic effect and identify molecular correlates that can predict...

Variant Histology Urothelial Carcinoma: A Patient Case - Makarand Khochikar

Details
Ashish Kamat, MD, welcomes Makarand Khochikar, President of the Urological Society of India – West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj joins to discuss a bladder cancer case from Dr. Khockikar’s case files. In this particular case, Dr. Khockikar reviews the cystoscopy of a 65-year-old male presented with intermittent hematuria and...

T2 N0 M0 High-grade Urothelial Carcinoma Patient Case Study with Cushingoid Features Undergoing Radical Cystectomy in Neobladder - Makarand Khochikar

Details
In a conversation with Ashish Kamat, MD, MBBS, Makarand Khochikar, MS DNB, Dip. Urol, FRCS, FEBU, presents a bladder cancer case study focusing on a patient with invasive T2 N0 M0 high-grade urothelial carcinoma. Dr. Khochikar describes both the process of perioperative counseling with the patient and the radical cystectomy that was surgically performed. Dr. Khochikar walks through the procedure a...

Clinically Node Positive Bladder Cancer and The Timing of Surgery - Neema Navai

Details
Ashish Kamat, MD, MBBS welcomes Neema Navai, MD, to this Bladder Cancer Center of Excellence discussion. Dr. Navai researches minimally metastatic and metastatic bladder cancer where surgical therapy can be implemented. Starting with a case study of a patient diagnosed with bladder cancer with an involved pelvic lymph node, Dr. Navai describes how outcomes regarding the use of surgery and chemothe...

The Management of Bladder Cancer During Pregnancy - Makarand Khochikar

Details
Makarand Khochikar, MS DNB, Dip Urol, FRCS, FEBU, presents a case study evaluating the care of a pregnant woman with bladder cancer, in a discussion with Ashish Kamat, MD, MBBS. Dr. Kamat discusses balancing the health of the mother and the health of the fetus, and Dr. Khochikar reviews the treatment the patient was given, including muscle-sparing resection of the tumor. Dr. Khochikar and Dr. Kama...

Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay

Details
Justin Matulay, MD, joins Ashish Kamat, MD, MBBS, to review his work assessing the variability in guideline management and adherence for non-muscle Invasive Bladder Cancer (NMIBC) among members of the Society for Urologic Oncology (SUO). As bladder cancer poses a significant risk to the population and most diagnoses are non-muscle invasive, Dr. Matulay and colleagues at MD Anderson Cancer Center w...

Urinary Diversion in Women Following Radical Cystectomy - Renu Eapen

Details
Ashish Kamat, MD, MBBS welcomes Renu Eapen, MD, to the UroToday Bladder Cancer Center of Excellence to dissect the gender-related differences in oncological and functional outcomes post-radical cystectomy. Women have been shown to face worse oncological outcomes with bladder cancer; explanations for this include social determinants such as initial diagnosis of urinary tract infection (UTI) prior t...